Tofacitinib also demonstrated significant therapeutic potential in SLE patients with arthritis in a retrospective cohort study, where tofacitinib resulted in a reduction in serum Il-6 levels and T cell activation (49). The gene discussed is IL6; the disease is systemic lupus erythematosus.